BOULDER, Colo., January 31, 2019 — SomaLogic is featured prominently in a press release announcing the first patient enrollment in a diabetes prevention study at the Leeds Centre for Personalised Medicine and Health in the UK. The trial uses personalized health insights derived from SomaLogic’s protein measurement technology to advise patients on lifestyle changes to help prevent the onset of type 2 diabetes.

More details are available in the press release, which can be accessed online here: